Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Calogero Cammà

Showing results (11-20 of 210) with videos related to

Pageof 21
Sort By:
Journal of Hepatology|December 17, 2005
Treatment options in HBVAntonio Craxì, Giorgio Antonucci, Calogero Cammà
Journal of Hepatology|October 3, 2022
Expert opinion vs. meta-analysis: To be or not to be?Calogero Cammà, Marco Enea, Ciro Celsa
Expert Review of Anticancer Therapy|February 23, 2018
Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?Marcello Maida, Giuseppe Cabibbo, Calogero Cammà
Hepatology (Baltimore, Md.)|July 22, 2014
Reply: To PMID 24691835Salvatore Petta, Giuseppe Cabibbo, Calogero Cammà
Gastroenterology|December 26, 2012
Reply: To PMID 22819864Erica Villa, Calogero Cammà, Dominique Valla
Journal of Hepatology|January 8, 2004
Interferon-alpha for HBeAg-positive chronic hepatitis BAntonio Craxì, Danilo Di Bona, Calogero Cammà
Current Pharmaceutical Design|July 29, 2004
The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approachCalogero Cammà, Danilo Di Bona, Antonio Craxì
Liver International : Official Journal of the International Association for the Study of the Liver|June 24, 2018
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?Giuseppe Cabibbo, Ciro Celsa, Calogero Cammà, et al.
Lancet (London, England)|April 9, 2002
Preoperative and postoperative radiotherapy and survival in colorectal cancerCalogero Cammà, Francesco Fiorica, Antonio Craxì, et al.
Digestive Diseases (Basel, Switzerland)|September 24, 2015
Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical PracticeGiuseppe Cabibbo, Salvatore Petta, Marcello Maida, et al.
Pageof 21

Showing results (11-20 of 210) with videos related to

Sort By:
Pageof 21
Journal of Hepatology|December 17, 2005
Treatment options in HBVAntonio Craxì, Giorgio Antonucci, Calogero Cammà
Journal of Hepatology|October 3, 2022
Expert opinion vs. meta-analysis: To be or not to be?Calogero Cammà, Marco Enea, Ciro Celsa
Expert Review of Anticancer Therapy|February 23, 2018
Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?Marcello Maida, Giuseppe Cabibbo, Calogero Cammà
Hepatology (Baltimore, Md.)|July 22, 2014
Reply: To PMID 24691835Salvatore Petta, Giuseppe Cabibbo, Calogero Cammà
Gastroenterology|December 26, 2012
Reply: To PMID 22819864Erica Villa, Calogero Cammà, Dominique Valla
Journal of Hepatology|January 8, 2004
Interferon-alpha for HBeAg-positive chronic hepatitis BAntonio Craxì, Danilo Di Bona, Calogero Cammà
Current Pharmaceutical Design|July 29, 2004
The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approachCalogero Cammà, Danilo Di Bona, Antonio Craxì
Liver International : Official Journal of the International Association for the Study of the Liver|June 24, 2018
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?Giuseppe Cabibbo, Ciro Celsa, Calogero Cammà, et al.
Lancet (London, England)|April 9, 2002
Preoperative and postoperative radiotherapy and survival in colorectal cancerCalogero Cammà, Francesco Fiorica, Antonio Craxì, et al.
Digestive Diseases (Basel, Switzerland)|September 24, 2015
Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical PracticeGiuseppe Cabibbo, Salvatore Petta, Marcello Maida, et al.
Pageof 21